Blood transfusion use in non-dialysis-dependent chronic kidney disease patients aged 65 years and older

Hassan N. Ibrahim; Areef Ishani; Haifeng Guo; David T. Gilbertson

doi:10.1093/ndt/gfp213

Blood transfusion use in non-dialysis-dependent chronic kidney disease patients aged 65 years and older

Hassan N. Ibrahim, Areef Ishani, Haifeng Guo, David T. Gilbertson

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Background. Erythropoiesis stimulating agents (ESA) have alleviated the need for blood transfusions in dialysis patients. Their impact on transfusion frequency in elderly chronic kidney disease (CKD) patients aged 65 years and older with non-dialysis-dependent CKD has not been studied.Methods. We conducted a retrospective cohort study of Medicare beneficiaries with CKD, point prevalent as of 1 January of each calendar year 1992-2004 (n = 301000), and a concurrent group of beneficiaries without CKD (n = 15772039). During the entry year, we used administrative claim data to assemble a comorbidity profile for each participant. Transfusion event rates, ESA use and parenteral iron use were of primary interest.Results. CKD patients were at least four times more likely than non-CKD patients to receive transfusions. Transfusion rates adjusted for case mix fell from 194.2 transfusions per 1000 patient-years in 1992 to 112.2 in 2004. The decline in transfusions was highest for anaemic CKD patients receiving ESAs, which were given to 0.8 of CKD patients in 1992 and to 7.5 in 2004.Conclusions. Transfusion use in non-dialysis-dependent CKD patients has decreased considerably but continues to be common. ESA use and possibly changed attitudes towards transfusion use explain most of the reduction noted.

Original language	English (US)
Pages (from-to)	3138-3143
Number of pages	6
Journal	Nephrology Dialysis Transplantation
Volume	24
Issue number	10
DOIs	https://doi.org/10.1093/ndt/gfp213
State	Published - Oct 2009

Bibliographical note

Funding Information:
1Chronic Disease Research Group, Minneapolis Medical Research Foundation, 2Department of Medicine, University of Minnesota and 3Section of Nephrology, Department of Medicine, Minneapolis Veterans Affairs Medical Center, Minneapolis, MN, USA

Funding Information:
Conflicts of interest statement. This study was supported by a research contract from Amgen Inc., Thousand Oaks, CA, USA. The contract provides for the authors to have final determination of the content of this manuscript. D.T.G. has received consulting fees from Amgen. H.N.I. and A.I. consult for, and H.G. is employed by, the Chronic Disease Research Group.

Keywords

Chronic kidney disease
Erythropoiesis stimulating agents
Transfusions

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1093/ndt/gfp213

Find It

Find It at U of M Libraries

Cite this

@article{410cf3a0e8604286bad7779155f23945,

title = "Blood transfusion use in non-dialysis-dependent chronic kidney disease patients aged 65 years and older",

abstract = "Background. Erythropoiesis stimulating agents (ESA) have alleviated the need for blood transfusions in dialysis patients. Their impact on transfusion frequency in elderly chronic kidney disease (CKD) patients aged 65 years and older with non-dialysis-dependent CKD has not been studied.Methods. We conducted a retrospective cohort study of Medicare beneficiaries with CKD, point prevalent as of 1 January of each calendar year 1992-2004 (n = 301000), and a concurrent group of beneficiaries without CKD (n = 15772039). During the entry year, we used administrative claim data to assemble a comorbidity profile for each participant. Transfusion event rates, ESA use and parenteral iron use were of primary interest.Results. CKD patients were at least four times more likely than non-CKD patients to receive transfusions. Transfusion rates adjusted for case mix fell from 194.2 transfusions per 1000 patient-years in 1992 to 112.2 in 2004. The decline in transfusions was highest for anaemic CKD patients receiving ESAs, which were given to 0.8 of CKD patients in 1992 and to 7.5 in 2004.Conclusions. Transfusion use in non-dialysis-dependent CKD patients has decreased considerably but continues to be common. ESA use and possibly changed attitudes towards transfusion use explain most of the reduction noted.",

keywords = "Chronic kidney disease, Erythropoiesis stimulating agents, Transfusions",

author = "Ibrahim, {Hassan N.} and Areef Ishani and Haifeng Guo and Gilbertson, {David T.}",

note = "Funding Information: 1Chronic Disease Research Group, Minneapolis Medical Research Foundation, 2Department of Medicine, University of Minnesota and 3Section of Nephrology, Department of Medicine, Minneapolis Veterans Affairs Medical Center, Minneapolis, MN, USA Funding Information: Conflicts of interest statement. This study was supported by a research contract from Amgen Inc., Thousand Oaks, CA, USA. The contract provides for the authors to have final determination of the content of this manuscript. D.T.G. has received consulting fees from Amgen. H.N.I. and A.I. consult for, and H.G. is employed by, the Chronic Disease Research Group.",

year = "2009",

month = oct,

doi = "10.1093/ndt/gfp213",

language = "English (US)",

volume = "24",

pages = "3138--3143",

journal = "Nephrology Dialysis Transplantation",

issn = "0931-0509",

publisher = "Oxford University Press",

number = "10",

}

TY - JOUR

T1 - Blood transfusion use in non-dialysis-dependent chronic kidney disease patients aged 65 years and older

AU - Ibrahim, Hassan N.

AU - Ishani, Areef

AU - Guo, Haifeng

AU - Gilbertson, David T.

N1 - Funding Information: 1Chronic Disease Research Group, Minneapolis Medical Research Foundation, 2Department of Medicine, University of Minnesota and 3Section of Nephrology, Department of Medicine, Minneapolis Veterans Affairs Medical Center, Minneapolis, MN, USA Funding Information: Conflicts of interest statement. This study was supported by a research contract from Amgen Inc., Thousand Oaks, CA, USA. The contract provides for the authors to have final determination of the content of this manuscript. D.T.G. has received consulting fees from Amgen. H.N.I. and A.I. consult for, and H.G. is employed by, the Chronic Disease Research Group.

PY - 2009/10

Y1 - 2009/10

N2 - Background. Erythropoiesis stimulating agents (ESA) have alleviated the need for blood transfusions in dialysis patients. Their impact on transfusion frequency in elderly chronic kidney disease (CKD) patients aged 65 years and older with non-dialysis-dependent CKD has not been studied.Methods. We conducted a retrospective cohort study of Medicare beneficiaries with CKD, point prevalent as of 1 January of each calendar year 1992-2004 (n = 301000), and a concurrent group of beneficiaries without CKD (n = 15772039). During the entry year, we used administrative claim data to assemble a comorbidity profile for each participant. Transfusion event rates, ESA use and parenteral iron use were of primary interest.Results. CKD patients were at least four times more likely than non-CKD patients to receive transfusions. Transfusion rates adjusted for case mix fell from 194.2 transfusions per 1000 patient-years in 1992 to 112.2 in 2004. The decline in transfusions was highest for anaemic CKD patients receiving ESAs, which were given to 0.8 of CKD patients in 1992 and to 7.5 in 2004.Conclusions. Transfusion use in non-dialysis-dependent CKD patients has decreased considerably but continues to be common. ESA use and possibly changed attitudes towards transfusion use explain most of the reduction noted.

AB - Background. Erythropoiesis stimulating agents (ESA) have alleviated the need for blood transfusions in dialysis patients. Their impact on transfusion frequency in elderly chronic kidney disease (CKD) patients aged 65 years and older with non-dialysis-dependent CKD has not been studied.Methods. We conducted a retrospective cohort study of Medicare beneficiaries with CKD, point prevalent as of 1 January of each calendar year 1992-2004 (n = 301000), and a concurrent group of beneficiaries without CKD (n = 15772039). During the entry year, we used administrative claim data to assemble a comorbidity profile for each participant. Transfusion event rates, ESA use and parenteral iron use were of primary interest.Results. CKD patients were at least four times more likely than non-CKD patients to receive transfusions. Transfusion rates adjusted for case mix fell from 194.2 transfusions per 1000 patient-years in 1992 to 112.2 in 2004. The decline in transfusions was highest for anaemic CKD patients receiving ESAs, which were given to 0.8 of CKD patients in 1992 and to 7.5 in 2004.Conclusions. Transfusion use in non-dialysis-dependent CKD patients has decreased considerably but continues to be common. ESA use and possibly changed attitudes towards transfusion use explain most of the reduction noted.

KW - Chronic kidney disease

KW - Erythropoiesis stimulating agents

KW - Transfusions

UR - http://www.scopus.com/inward/record.url?scp=70349482089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349482089&partnerID=8YFLogxK

U2 - 10.1093/ndt/gfp213

DO - 10.1093/ndt/gfp213

M3 - Article

C2 - 19451656

AN - SCOPUS:70349482089

SN - 0931-0509

VL - 24

SP - 3138

EP - 3143

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

IS - 10

ER -

Blood transfusion use in non-dialysis-dependent chronic kidney disease patients aged 65 years and older

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this